Acceleron Pharma Inc (XLRN)

30.51
0.19 0.63
NASDAQ : Health Care
Prev Close 30.32
Open 30.15
Day Low/High 30.12 / 30.77
52 Wk Low/High 21.93 / 50.86
Volume 23.07K
Avg Volume 288.00K
Exchange NASDAQ
Shares Outstanding 37.60M
Market Cap 1.14B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016

Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors

Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases

Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today

Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "perilous reversal" (up big yesterday but down big today) candidate

Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock

Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease

Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.

Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock

Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ: CELG) today announced that preliminary results will be presented from an ongoing long-term Phase 2 extension study in patients with beta-thalassemia...

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ: CELG), today announced preliminary results from an ongoing long-term Phase 2 extension study with luspatercept in patients with lower risk myelodysplastic...

Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association

Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma To Host First Quarter 2016 Financial Results

Acceleron Pharma To Host First Quarter 2016 Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a strong on high relative volume candidate

Acceleron Pharma To Participate In Four Healthcare Investor Conferences In March

Acceleron Pharma To Participate In Four Healthcare Investor Conferences In March

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights

Acceleron Pharma Reports Fourth Quarter And Year Ended 2015 Financial And Operational Results And Recent Highlights

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

19 Charts to Calm Your Recession Fears

19 Charts to Calm Your Recession Fears

Is it better to choose stocks through fundamental or technical analysis? Real Money's Bruce Kamich puts his technical spin on these recession-proof stocks chosen by Morgan Stanley analysts.

Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results

Acceleron Pharma To Host Fourth Quarter And Year Ended 2015 Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

19 Stocks You Should Own if the U.S. Falls Into a Recession

19 Stocks You Should Own if the U.S. Falls Into a Recession

As speculation mounts that the U.S. economy will enter a recession, here are 19 stocks you should own just in case.

Acceleron Pharma Enters Oversold Territory (XLRN)

Acceleron Pharma Enters Oversold Territory (XLRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today...

5 Stocks to Trade for Breakout Gains

5 Stocks to Trade for Breakout Gains

These stocks look ready to break out and trade higher from current levels.

Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders

Insider Trading Alert - XLRN, TTMI And AGX Traded By Insiders

Stocks with insider trader activity include XLRN, TTMI and AGX

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open

Acceleron Pharma (XLRN) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a pre-market mover with heavy volume candidate